New treatment strategies for advanced-stage gastrointestinal stromal tumours

Nature Reviews Clinical Oncology, Published online: 25 February 2022; doi:10.1038/s41571-022-00606-4Gastrointestinal stromal tumour (GIST) is the most common form of sarcoma and has become a paradigm of precision medicine owing to the fact that almost all patients harbour one of several known molecule drivers, most of which can be targeted therapeutically. Nevertheless, novel therapeutic strategies are required to overcome the intrinsic resistance of certain subtypes of GIST to existing treatments as well as the acquired resistance that eventually arises in initially sensitive subtypes. This Review describes the biology of GIST, the evolution of the current treatments for this cancer, and the emerging therapeutic agents and approaches that might overcome the remaining clinical challenges.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research